SyntekaBio, Inc. (KOSDAQ: 226330)
South Korea
· Delayed Price · Currency is KRW 5,690.00
+110.00 (1.97%)
Oct 11, 2024, 9:00 AM KST
SyntekaBio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 124.38 | 123.41 | 243.99 | 316.66 | 609.68 |
| Revenue Growth (YoY) | 36.91% | -49.42% | -22.95% | -48.06% | - |
| Cost of Revenue | 2.57 | 2.48 | 10.96 | 15.24 | 25.84 |
| Gross Profit | 121.82 | 120.92 | 233.04 | 301.42 | 583.84 |
| Selling, General & Admin | 7,948 | 7,477 | 7,456 | 4,828 | 4,418 |
| Research & Development | 2,970 | 3,225 | 3,177 | 3,101 | 2,108 |
| Other Operating Expenses | 186.88 | 187.25 | 149.85 | 106.24 | 98.17 |
| Operating Expenses | 12,918 | 12,397 | 12,025 | 9,193 | 7,681 |
| Operating Income | -12,797 | -12,276 | -11,792 | -8,891 | -7,097 |
| Interest Expense | -753.53 | -375.74 | -1,251 | -254.17 | -84.36 |
| Interest & Investment Income | 809.61 | 1,171 | 971.76 | 374.41 | 690.86 |
| Currency Exchange Gain (Loss) | -0.67 | -0.35 | 2.59 | 0.22 | - |
| Other Non Operating Income (Expenses) | 5,935 | 758.7 | 7,583 | -6,032 | 2.73 |
| EBT Excluding Unusual Items | -6,806 | -10,723 | -4,486 | -14,803 | -6,488 |
| Gain (Loss) on Sale of Assets | -5.73 | - | 0.13 | - | 0.15 |
| Asset Writedown | -5.75 | -72 | -20.25 | - | - |
| Other Unusual Items | -603.08 | -603.08 | - | - | - |
| Pretax Income | -7,421 | -11,398 | -4,506 | -14,803 | -6,488 |
| Net Income | -7,421 | -11,398 | -4,506 | -14,803 | -6,488 |
| Net Income to Common | -7,421 | -11,398 | -4,506 | -14,803 | -6,488 |
| Shares Outstanding (Basic) | 15 | 14 | 14 | 13 | 13 |
| Shares Outstanding (Diluted) | 15 | 14 | 14 | 13 | 13 |
| Shares Change (YoY) | 10.75% | 5.94% | 0.37% | 1.65% | - |
| EPS (Basic) | -488.87 | -796.14 | -333.47 | -1099.43 | -489.80 |
| EPS (Diluted) | -899.75 | -796.14 | -333.47 | -1099.43 | -490.00 |
| Free Cash Flow | -22,636 | -17,442 | -16,899 | -13,520 | -5,457 |
| Free Cash Flow Per Share | -1491.20 | -1218.35 | -1250.52 | -1004.13 | -411.97 |
| Gross Margin | 97.94% | 97.99% | 95.51% | 95.19% | 95.76% |
| Operating Margin | -10288.07% | -9947.91% | -4832.99% | -2807.83% | -1164.08% |
| Profit Margin | -5966.30% | -9235.91% | -1846.96% | -4674.69% | -1064.13% |
| Free Cash Flow Margin | -18198.95% | -14133.89% | -6926.24% | -4269.46% | -895.05% |
| EBITDA | -10,725 | -10,514 | -10,319 | -7,733 | -6,040 |
| D&A For EBITDA | 2,072 | 1,762 | 1,473 | 1,158 | 1,058 |
| EBIT | -12,797 | -12,276 | -11,792 | -8,891 | -7,097 |
| Advertising Expenses | - | - | - | - | 6 |
Source: S&P Capital IQ. Standard template. Financial Sources.